MetaCap

Aethlon Medical (AEMD) vs Femasys (FEMY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Femasys is the larger company by market cap ($10.7 million vs $8.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AEMD-10.05%FEMY-38.00%
+5%-21%-46%
Oct 7, 20261 yearNov 20, 2026
AEMD-9.75%FEMY-38.00%
+2%-19%-40%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AEMD versus FEMY key metrics
MetricAEMDFEMY
Share price$5.46$1.24
Market cap$8.78M$10.73M
1-day change+12.81%0.00%
YTD return—-89.24%
1-year return—-93.26%
5-year return—-98.63%
EPS (TTM)$-16.22$-1.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.29M
Revenue growth (YoY)—+40.77%
Net income (latest FY)$-7.15M$-18.63M
Gross margin—61.96%
Operating margin—-766.95%
Net margin—-812.27%
52-week high$24.75$20.80
52-week low$1.41$1.07
Distance from 52-week high-77.94%-94.04%
Analyst consensusnonenone
Avg. price target upside+142.67%+1055.65%
Average volume2.56M110.75K
Shares outstanding1.61M8.66M
Employees951
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aethlon Medical

AEMD stock →

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states.

Health Care · Medical/Dental Instruments · 9 employees

About Femasys

FEMY stock →

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.

Health Care · Medical/Dental Instruments · 51 employees

AEMD vs FEMY FAQ

Which is bigger, Aethlon Medical or Femasys?

Femasys (FEMY) is larger, with a market capitalization of $10.73M compared with $8.78M for Aethlon Medical (AEMD).

Are Aethlon Medical and Femasys in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons